NCT06989333View on ClinicalTrials.gov

Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Pulmonary Alveolar Proteinosis
Interventions
DRUG

GM-CSF (granulocyte-macrophage colony-stimulating factor)

Bronchoscopy under general anesthesia or sedation; The predetermined dose of recombinant GM-CSF was dissolved in normal saline. The diseased lung segments were located through bronchoscopy and the liquid medicine was sprayed.

All Listed Sponsors
lead

Jiuwu Bai

OTHER